Oxford Biomedica announces a £2 million two year collaboration co-funded by Innovate UK. We are looking forward to working as a member of such a strong partnership and seeing our Ranger adaptive control technology actively contributing to the accelerated development of novel, cost-effective therapies.
We are pleased to welcome Remy Martin as Business Development Manager. Remy brings a wealth of experience and knowledge of upstream process development, process control and sensor technologies.
We are happy to confirm our membership of the recently established National Institute for Innovation in Manufacturing Biopharmaceuticals in the US. The company's membership was signed at NIIMBL's inaugral meeting Washington DC in May 2017, which was attended by Stratophase's CEO Simon Saxby.
We are pleased to announce our joint collaboration agreement with Merck, a leading science and technology company. The collaboration will see the application of our Ranger technology to Merck's cell culture manufacturing platforms and the development of dynamic control strategies that enable complex feeding regimes to be optimised and controlled in real time.
We are pleased to announce that Simon Saxby has been appointed Chief Executive Office as of 11 August 2016. Former CEO, Bill Campbell will join the Board as of that date.
Mr Saxby has over thirty years international experience in life sciences, as a CEO of both public and private companies.